drugset / Trial / NCT00023985

Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer

NCT00023985

Phase 1 Completed Roswell Park Cancer Institute
Treatment

Summary

RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have non-small cell lung cancer.

Timeline

Start
2001-01
Primary completion
2003-07
Completion
2003-08

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous tumor cell vaccine Vaccine Subcutaneous
Subject therapeutic autologous dendritic cells Vaccine Subcutaneous

Indications